close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

32.14 -0.32 (-0.99%)
Streaming Delayed Price Updated: 3:01 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
News headline image
Expert Ratings For Viridian Therapeutics ↗
 
Via Benzinga
News headline image
3 Small-Cap Stocks With Explosive 2X Growth Potential ↗
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
7 Analysts Assess Viridian Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On Viridian Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Navigating 6 Analyst Ratings For Viridian Therapeutics ↗
 
Via Benzinga
News headline image
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20 ↗
Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them. 
Via InvestorPlace
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving ↗
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering. 
Via Benzinga
News headline image
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today